Altimmune, Inc.ALTEarnings & Financial Report
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, vaccines, and peptide-based therapies. Its pipeline covers infectious disease prevention, liver disease treatments, and metabolic disorder therapies, serving global biopharmaceutical and healthcare markets while advancing candidates through clinical trials.
Revenue
$5.0K
Gross Profit
N/A
Operating Profit
$-22.9M
Net Profit
$-22.1M
Gross Margin
N/A
Operating Margin
-458440.0%
Net Margin
-442920.0%
YoY Growth
0.0%
EPS
$-0.27
Altimmune, Inc. Q2 FY2025 Financial Summary
Altimmune, Inc. reported revenue of $5.0K (up 0.0% YoY) for Q2 FY2025, with a net profit of $-22.1M (up 10.1% YoY) (-442920.0% margin).
Key Financial Metrics
| Total Revenue | $5.0K |
|---|---|
| Net Profit | $-22.1M |
| Gross Margin | N/A |
| Operating Margin | -458440.0% |
| Report Period | Q2 FY2025 |
Altimmune, Inc. Annual Revenue by Year
Altimmune, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $41.0K).
| Year | Annual Revenue |
|---|---|
| 2025 | $41.0K |
| 2024 | $20.0K |
| 2023 | $426.0K |
| 2022 | $-68.0K |
Altimmune, Inc. Quarterly Revenue & Net Profit History
Altimmune, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $26.0K | +420.0% | N/A | N/A |
| Q3 FY2025 | $5.0K | +0.0% | $-19.0M | -380280.0% |
| Q2 FY2025 | $5.0K | +0.0% | $-22.1M | -442920.0% |
| Q1 FY2025 | $5.0K | +0.0% | $-19.6M | -391500.0% |
| Q4 FY2024 | $5.0K | -86.5% | N/A | N/A |
| Q3 FY2024 | $5.0K | -98.6% | $-22.8M | -456900.0% |
| Q2 FY2024 | $5.0K | -16.7% | $-24.6M | -492800.0% |
| Q1 FY2024 | $5.0K | -76.2% | $-24.4M | -487880.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5000 | $5000 | $5000 | $5000 | $5000 | $5000 | $5000 | $26000 |
| YoY Growth | -76.2% | -16.7% | -98.6% | -86.5% | 0.0% | 0.0% | 0.0% | 420.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $188.4M | $173.3M | $147.9M | $139.3M | $157.3M | $190.3M | $218.4M | $279.9M |
| Liabilities | $15.4M | $20.8M | $14.5M | $15.8M | $15.1M | $29.0M | $32.8M | $55.0M |
| Equity | $172.9M | $152.5M | $133.4M | $123.5M | $142.2M | $161.4M | $185.6M | $224.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-16.4M | $-18.1M | $-27.1M | $-79.8M | $-16.8M | $-19.4M | $-11.9M | $-67.5M |